bluuebunny/crossref_metadata_2025_split huggingface dataset:
Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice
Authors: Taddio Marco F. , Doshi Suraj , Masri Marwan , Jeanjean Pauline , Hikmat Firas , Gerlach Alana , Nyiranshuti Lea , Rosser Ethan W. , Schaue Dorthe , Besserer-Offroy Elie , Carlucci Giuseppe , Radu Caius G. , Czernin Johannes , Lückerath Katharina , Mona Christine E. 
Published: July 2024

Abstract
Purpose
Fibroblast Activation Protein (FAP) is an emerging theranostic target that is highly expressed on cancer-associated fibroblasts and on certain tumor cells including sarcoma. We investigated the anti-tumor efficacy of [225Ac]Ac-FAPI-46 as monotherapy or in combination with immune checkpoint blockade (ICB) in immunocompetent murine models of sarcoma sensitive or resistant to ICB.

Methods
[68Ga]Ga- and [225Ac]Ac-FAPI-46 were tested in subcutaneous FAP+ FSA fibrosarcoma bearing C3H/Sed/Kam mice. The efficacy of up to three cycles of 60 kBq [225Ac]Ac-FAPI-46 was evaluated as monotherapy and in combination with an anti-PD-1 antibody. Efficacy of [225Ac]Ac-FAPI-46 and/or ICB was further compared in FAP-overexpressing FSA (FSA-F) tumors that were sensitive to ICB or rendered ICB-resistant by tumor-induction in the presence of Abatacept.

Results
[225Ac]Ac-FAPI-46 was well tolerated up to 3 × 60 kBq but had minimal effect on FSA tumor growth. The combination of three cycles [225Ac]Ac-FAPI-46 and ICB resulted in growth delay in 55% of mice (6/11) and partial tumor regression in 18% (2/11) of mice. In FSA-F tumors with FAP overexpression, both [225Ac]Ac-FAPI-46 and ICB were effective without additional benefits from the combination. In locally immunosuppressed and ICB resistant FAP-F tumors, however, [225Ac]Ac-FAPI-46 restored responsiveness to ICB, resulting in significant tumor regression and tumor-free survival of 56% of mice in the combination group up to 60 days post treatment.

Conclusion
[225Ac]Ac-FAPI-46 efficacy is correlated with tumoral FAP expression levels and can restore responsiveness to PD-1 ICB. These data illustrate that careful patient selection based on target expression and rationally designed combination therapies are critically important to maximize the therapeutic impact of FAP-targeting radioligands.
Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile
Authors: Liu Yongsheng , Oroujeni Maryam , Liao Yunqi , Vorobyeva Anzhelika , Bodenko Vitalina , Orlova Anna , Konijnenberg Mark , Carlqvist Matilda , Wahlberg Elisabet , Loftenius Annika , Frejd Fredrik Y , Tolmachev Vladimir 
Published: July 2024

Abstract
Purpose
Fusion of Affibody molecules with an albumin-binding domain (ABD) provides targeting agents, which are suitable for radionuclide therapy. To facilitate clinical translation, the low immunogenic potential of such constructs with targeting properties conserved is required.

Methods
The HER2-targeting Affibody molecule ZHER2:2891 was fused with a deimmunized ABD variant and DOTA was conjugated to a unique C-terminal cysteine. The novel construct, PEP49989, was labelled with 177Lu. Affinity, specificity, and in vivo targeting properties of [177Lu]Lu-PEP49989 were characterised. Experimental therapy in mice with human HER2-expressing xenografts was evaluated.

Results
The maximum molar activity of 52 GBq/µmol [177Lu]Lu-PEP49989 was obtained. [177Lu]Lu-PEP49989 bound specifically to HER2-expressing cells in vitro and in vivo. The HER2 binding affinity of [177Lu]Lu-PEP49989 was similar to the affinity of [177Lu]Lu-ABY-027 containing the parental ABD035 variant. The renal uptake of [177Lu]Lu-PEP49989 was 1.4-fold higher, but hepatic and splenic uptake was 1.7-2-fold lower than the uptake of [177Lu]Lu-ABY-027. The median survival of xenograft-bearing mice treated with 21 MBq [177Lu]Lu-PEP49989 (> 90 days) was significantly longer than the survival of mice treated with vehicle (38 days) or trastuzumab (45 days). Treatment using a combination of [177Lu]Lu-PEP49989 and trastuzumab increased the number of complete tumour remissions. The renal and hepatic toxicity was minimal to mild.

Conclusion
In preclinical studies, [177Lu]Lu-PEP49989 demonstrated favourable biodistribution and a strong antitumour effect, which was further enhanced by co-treatment with trastuzumab.
Dual-Plane Midface Lift Through Transoral and Transtemporal Approach
Authors: Gencer Mehmet , Kerem Metin , Sağlam Yunus , Tatar Burak Ergün 
Published: July 2024

Abstract
Introduction
The surge in the popularity of midface and temporal lifting procedures can be attributed to evolving social media trends and heightened patient expectations, particularly among younger individuals seeking “beautification” rather than traditional rejuvenation. Scarless techniques, such as transtemporal/transoral approaches, are increasingly preferred. This study aimed to combine the advantages of both superficial and deep dissection planes in midface and temporal lifting procedures.

Methods
This retrospective study included 184 patients who underwent surgery using a dual-plane midface and temporal lift technique. Preoperative and postoperative assessments, including P1/P2 ratio calculations, were performed to evaluate volumetric distribution in the midface.

Results
The study cohort exhibited a significant improvement in the P1/P2 ratio postoperatively (p < 0.05), indicating successful volume redistribution. Complications, including hypoesthesia, bruising, and infection, were managed effectively. Minor asymmetries were observed, with revisions offered, but declined by the patient.

Discussion
This technique offers hidden incisions and reduces the risk of scar-related complications, making it suitable for patients seeking facial enhancement. Addressing the tear trough area and the lateral canthus provides comprehensive facial rejuvenation. The dual-plane approach facilitates both skin mobilization and volume shift, yielding favorable aesthetic outcomes.

Conclusions
The dual-plane midface and temporal lift technique presented in this study offers a bi-vectoral approach to midfacial lifting, suitable for both beautification and rejuvenation goals. Despite the potential limitations, including infection risk, this method is an effective option for facial enhancement.

Level of Evidence II
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Selenium loaded sodium alginate/polyvinyl alcohol nanocomposite film as wound dressing: structural, optical, mechanical, antimicrobial properties and biocompatibility
Authors: Ibrahim Manar A. , Nasrallah Doaa A. , EL-Sayed Naglaa M. , Farag Omar F. 
Published: July 2024

AbstractIn the current research, synthesized Se-NPs were loaded into sodium alginate/polyvinyl alcohol SA/PVA blend, 1:2 (w:w), with different proportions to form nanocomposite films by using the solution casting method. The main goal is to enhance the physical and antibacterial properties of the polymer blend; therefore, it can be utilized for wound dressing applications. The physical aspects of the prepared films were characterized by X-ray diffraction (XRD), Fourier transform infrared (FTIR), atomic force microscope (AFM), scanning electron microscope (SEM), Energy dispersive X-ray (EDX), UV–Vis spectroscopic technique, and mechanical analysis to show the effect of increasing the concentration of Se-NPs from zero to 0.5 wt% on their properties. Regarding the XRD analysis, the calculated values of lattice strain ($$\varepsilon$$
ε
) increased from 0.005 to 0.013. The FTIR absorption spectrum recorded an intensity reduction and position shift in the main characteristic peaks of SA/PVA. The morphology of Se-NPs revealed a spherical shape with a mean diameter of 131.76 nm, as revealed by transmission electron microscopy (TEM). The surface morphological images showed the appearance of a few cracks; besides, the average roughness increased from 1.59 to 2.08 nm. According to the UV–Vis spectroscopic analysis, the optical band gap reduces (from 5.425 to 5.216 eV) for the direct transition and from (5.07–4.78 eV) for the indirect transition, which is an indication of the interaction between Se-NPs and SA/PVA blend. Young’s modulus, tensile strength, and yield strength of the films increased with the addition of selenium nanoparticles. On the other hand, the amount of selenium release significantly increased with enhancing the concentration of Se-NPs in SA/PVA blend film from 0.1 to 0.5 wt%. Additionally, the inclusion of Se-NPs supplied the polymer blend with excellent antimicrobial activity, which would remove the possibility of microbial infection at the wound site. Moreover, the prepared SA/PVA/Se nanocomposite films have good biocompatibility with Human Skin Fibroblast (HSF). The results suggest the potential of this nanocomposite to be used in wound dressing applications.
Physical Zero-Knowledge Proof for Sukoro
Authors: Sasaki Shun , Shinagawa Kazumasa 
Published: July 2024

AbstractA zero-knowledge proof protocol is a cryptographic protocol in which a prover, who knows the witness to a statement, can convince a verifier that the statement is true without revealing any information about the witness. Although zero-knowledge proof protocols are typically executed on electronic computers, there is a line of research to design zero-knowledge proof protocols based on physical objects (e.g., a deck of cards). This is called physical zero-knowledge proof. In this paper, we construct a physical zero-knowledge proof protocol for a logical puzzle called Sukoro. Sukoro has many cells on the puzzle board, like Sudoku, where each cell must be empty or filled with a number from one to four, and each number must match the number of adjacent filled cells, and the same numbers must not be adjacent to each other. In addition, it has a rule that all filled cells must be connected, which is called the connectivity condition. Although some existing protocols deal with the connectivity condition, all existing methods are interactive, which requires the prover’s knowledge to determine how the cards are manipulated during the execution of the protocols. In this paper, we give a new method for verifying the connectivity condition in the non-interactive setting, which means that the protocol can be executed without the prover’s knowledge, and construct a physical zero-knowledge proof protocol for Sukoro.
Assessing the suitability of video-assisted anal fistula treatment for obese patients compared to conventional surgery: a question worth investigating
Authors: Tang Xiao-Li , Xu Zi-Yang , Yang Jun , Yang Zhe , Wang Zhi-Gang , Zhang Zheng-Yun , Yao Jing 
Published: July 2024

AbstractBackground and aimsVideo-assisted anal fistula treatment (VAAFT) is an innovative surgical approach enabling the direct visualization of the fistula tract structure. This study aims to assess the efficacy of VAAFT in comparison with that of traditional surgical methods and explore potential risk factors contributing to fistula recurrence to provide new recommendations for surgical selection.Materials and methodsInformation was collected from 100 patients with complex anal fistula (CAF) in our hospital who underwent surgical treatment from January 2021 to January 2023. We compared the baseline information and surgical outcomes of two groups, analyzed the risk factors for fistula recurrence by using logistic regression analysis, and conducted further exploration by using the body mass index.ResultsEqual numbers of patients underwent VAAFT and traditional surgeries, and no significant differences in baseline information were observed. Patients who received VAAFT experienced less intraoperative bleeding (15.5 (14.0–20.0) vs. 32.0 (25.0–36.0)), shorter hospital stays (2.0 (2.0–2.5) vs. 3.0 (3.0–3.5)), reduced postoperative pain and wound discharge, but longer operative times (43.3 ± 6.9 vs. 35.0 (31.5–40.0)) compared with patients who underwent traditional surgeries. No significant differences in recurrence rates were found three and six months after operation (thep-values were 0.790 and 0.806, respectively). However, the Wexner scores of the VAAFT group were significantly low in the first follow-up (0 (0–1.0) vs. 2.0 (1.0–2.0)). Postoperative recurrence of fistulas may be associated with obesity (p-value = 0.040), especially in patients undergoing traditional surgeries (p-value = 0.036).ConclusionVAAFT offers advantages, such as less pain, less trauma, and faster recovery, compared with traditional surgical treatment. Obese patients with CAF are prone to recurrence, and we recommend that they undergo VAAFT treatment rather than traditional surgeries.
Fresh osteochondral allograft transplantation for knee full-thickness articular cartilage lesions using femoral head of living donors: short-term results
Authors: Soubih Hesham Ossama , Al-Saed Ahmed M. , Ghazaly Sherif A. El , Sobhy Mohamed H. , Kamel Muhammad Elsayed , Ebied Wessam Fakhry , Haroun Haitham K. 
Published: July 2024

Abstract
Background
Fresh osteochondral allograft transplantation is a good treatment option of cartilage defects. However, this treatment option is not available in all countries due to limited graft availability and tissue banks limitations. The purpose of this study is to assess the short term functional and imaging outcomes of fresh osteochondral allograft transplantation in the knee using the femoral head of living donors.

Hypothesis
Fresh osteochondral allografts from the femoral heads of living donors is a valid graft source for management of distal Femur cartilage defects. This technique can improve functional knee scores with good radiological outcomes.

Study Design
Prospective case series.

Methods
Fifteen patients with full thickness cartilage defects of the distal femur underwent osteochondral allograft transplantation from the femoral heads of living donors. Grafts were transplanted by both shell and multiple dowels techniques. The average follow up duration was 18.3 months (range, 12–25 months). Patients were evaluated by Lysholm and International Knee Documentation Committee (IKDC) scores, radiography and MR imaging using Osteochondral Allograft MRI Scoring System (OCAMRISS).

Results
There was a statistically significant improvement (P < 0.001) in both Lysholm and IKDC average scores at 6 months and 12 months postoperative. Postoperative MRI was done at an average 6.8 months (range, 5–11 months) postoperative. The mean total OCAMRISS score was 3.4 (range, 1–7). A second look arthroscopy was done in four patients and showed intact articular cartilage in all three patients.

Conclusion
Femoral head of living donors is a valid new source for fresh osteochondral allograft transplantation of knee osteochondral lesions. Short term results showed improvement in clinical assessment scores. Follow up imaging showed graft incorporation and good MRI scores.
Scaphocapitate arthrodesis with lunate preservation for Kienböck’s disease: prospective outcomes study
Authors: Hegazy Galal , Fouaad Amro A. , El-Sadek Rashed Emam , Zayed Emad , Saqr Yasser , Alshal Ehab 
Published: July 2024

Abstract
Purpose
The study evaluated the efficacy of SC arthrodesis with lunate preservation for treating patients diagnosed with stage IIIB or IIIC Kienböck’s disease, who also exhibit neutral ulnar variance. The study further aimed to explore potential variations in outcomes between patients diagnosed with stage IIIB and IIIC Kienböck’s disease.

Methods
Thirty-two patients diagnosed with stage IIIB (n = 19) and stage IIIC (n = 13) Kienböck’s disease underwent SC arthrodesis with distal radius bone grafting stabilised by Herbert compression screws. All participants underwent pre- and post-operative assessments including VAS score for pain, ROM, grip strength, MMWS, and the Quick DASH score. Additionally, RS angle, LHI ratio, and CHI ratio were assessed.

Results
For all patients, the mean operative time was 73 min, follow-up was 45.6 months, time to union was 14 weeks, and time to full return to work was 24 weeks. The rate of union at the arthrodesis site was 91% (29 out of 32 patients) whilst the incidence of postoperative degenerative arthritis was 36% (8 out of 32 patients). Regarding changes in the means of outcomes from pre- to post-operatively, the VAS score decreased from 8.2 to 1.3 and grip strength improved from 36 to 79%. The RS angle was corrected from 59° to 50°. Significant improvements were noted in the mean MMWS from 45 to 75 and QuickDASH score from 78 to 21. However, no significant changes were observed in ROM, LHI, and CHI. There were no significant differences between patients with stage IIIB and stage IIIC in terms of these parameters, except for differences observed in the RS angle, LHI, and CHI preoperatively and in LHI and CHI postoperatively.

Conclusion
Evidence level: II.
Our research demonstrates that SC arthrodesis is a valuable approach for reducing pain, improving grip strength, and enhancing overall function in individuals with advanced Kienböck’s disease. Importantly, our results indicate no notable differences in outcomes between patients diagnosed with stage IIIB or IIIC Kienböck’s disease.
Reviewing hereditary connective tissue disorders: Proposals of harmonic medicolegal assessments
Authors: Galante Nicola , Bedeschi Maria Francesca , Beltrami Benedetta , Bailo Paolo , Silva Palomino Laura Alicia , Piccinini Andrea 
Published: July 2024

AbstractHereditary connective tissue disorders (HCTDs) are a heterogeneous group of inherited diseases. These disorders show genetic mutations with loss of function of primary components of connective tissue, such as collagen and elastic fibers. There are more than 200 conditions that involve hereditary connective tissue disorders, while the most known are Marfan syndrome, Osteogenesis Imperfecta, and Ehlers-Danlos syndromes. These disorders need continuous updates, multidisciplinary skills, and specific methodologic evaluations sharing many medicolegal issues. Marfan syndrome and Ehlers-Danlos syndromes show a high risk of early sudden death. As a consequence of this, postmortem genetic testing can identify novel genotype–phenotype correlations which help the clinicians to assess personalized cardiovascular screening programs among the ill subjects. Genetic testing is also essential to identify children suffering from Osteogenesis Imperfecta, especially when a physical abuse is clinically suspected. However, this is a well-known clinical problem even though there are still challenges to interpret genetic data and variants of unknown significance due to the current extensive use of new genetic/genomic techniques. Additionally, the more significant applications and complexities of genomic testing raise novel responsibilities on the clinicians, geneticists, and forensic practitioners as well, increasing potential liability and medical malpractice claims. This systematic review provides a detailed overview on how multidisciplinary skills belonging to clinicians, medicolegal consultants, radiologists, and geneticists can cooperate to manage HCTDs from autopsy or clinical findings to genetic testing. Thus, technical aspects need to be addressed to the medicolegal community since there is no consensus works or guidelines which specifically discuss these issues.
Stability of N-type inactivation and the coupling between N-type and C-type inactivation in the Aplysia Kv1 channel
Authors: Iwamuro Tokunari , Itohara Kazuki , Furukawa Yasuo 
Published: July 2024

AbstractThe voltage-dependent potassium channels (Kv channels) show several different types of inactivation. N-type inactivation is a fast inactivating mechanism, which is essentially an open pore blockade by the amino-terminal structure of the channel itself or the auxiliary subunit. There are several functionally discriminatable slow inactivation (C-type, P-type, U-type), the mechanism of which is supposed to include rearrangement of the pore region. In some Kv1 channels, the actual inactivation is brought about by coupling of N-type and C-type inactivation (N-C coupling). In the present study, we focused on the N-C coupling of the Aplysia Kv1 channel (AKv1). AKv1 shows a robust N-type inactivation, but its recovery is almost thoroughly from C-type inactivated state owing to the efficient N-C coupling. In the I8Q mutant of AKv1, we found that the inactivation as well as its recovery showed two kinetic components apparently correspond to N-type and C-type inactivation. Also, the cumulative inactivation which depends on N-type mechanism in AKv1 was hindered in I8Q, suggesting that N-type inactivation of I8Q is less stable. We also found that Zn$$^{2+}$$

2
+

specifically accelerates C-type inactivation of AKv1 and that H382 in the pore turret is involved in the Zn$$^{2+}$$

2
+

binding. Because the region around Ile$$^8$$

8

(I8) in AKv1 has been suggested to be involved in the pre-block binding of the amino-terminal structure, our results strengthen a hypothesis that the stability of the pre-block state is important for stable N-type inactivation as well as the N-C coupling in the Kv1 channel inactivation.
Identification of homologs of the Chlamydia trachomatis effector CteG reveals a family of Chlamydiaceae type III secreted proteins that can be delivered into host cells
Authors: Pereira Inês Serrano , da Cunha Maria , Leal Inês Pacheco , Luís Maria Pequito , Gonçalves Paula , Gonçalves Carla , Mota Luís Jaime 
Published: July 2024

AbstractChlamydiae are a large group of obligate endosymbionts of eukaryotes that includes the Chlamydiaceae family, comprising several animal pathogens. Among Chlamydiaceae, Chlamydia trachomatis causes widespread ocular and urogenital infections in humans. Like many bacterial pathogens, all Chlamydiae manipulate host cells by injecting them with type III secretion effector proteins. We previously characterized the C. trachomatis effector CteG, which localizes at the host cell Golgi and plasma membrane during distinct phases of the chlamydial infectious cycle. Here, we show that CteG is a Chlamydiaceae-specific effector with over 60 homologs phylogenetically categorized into two distinct clades (CteG I and CteG II) and exhibiting several inparalogs and outparalogs. Notably, cteG I homologs are syntenic to C. trachomatis cteG, whereas cteG II homologs are syntenic among themselves but not with C. trachomatis cteG. This indicates a complex evolution of cteG homologs, which is unique among C. trachomatis effectors, marked by numerous events of gene duplication and loss. Despite relatively modest sequence conservation, nearly all tested CteG I and CteG II proteins were identified as type III secretion substrates using Yersinia as a heterologous bacterial host. Moreover, most of the type III secreted CteG I and CteG II homologs were delivered by C. trachomatis into host cells, where they localized at the Golgi region and cell periphery. Overall, this provided insights into the evolution of bacterial effectors and revealed a Chlamydiaceae family of type III secreted proteins that underwent substantial divergence during evolution while conserving the capacity to localize at specific host cell compartments.